Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab

Ignacio Garcia-Valladares, Raquel Cuchacovich, Luis R Espinoza

Section of Rheumatology, Department of Internal Medicine, LSU Health Sciences Center, New Orleans, LA, USA

Abstract: The development of psoriasis and psoriatic arthritis is a multistep process that leads to chronic or recurrent inflammation. Recent studies have suggested the importance of T helper (TH)1 and TH17 cells, accessory cells, and proinflammatory cytokines in the pathogenesis of the enthesis, synovium, and skin involvement in psoriasis in the presence of susceptibility genes that remain quiescent until triggered. Biologics, such as soluble CTLA-4 immunoglobulin, tumor necrosis factor (TNF) inhibitors, and ustekinumab, inhibit T cell activation which eventually leads to further stimulation of the interleukin 12, 17, and 23 axis, TNF-α, and lymphotoxin-α. Treatment with TNF-α blockers has been effective in refractory psoriasis and psoriatic arthritis, but there is still a subgroup of patients who do not respond to TNF inhibitors and, paradoxically, when treated, may develop TNF-induced psoriasis. Ustekinumab, because of its different mechanism of action at the level of the interleukin 12, 17, and 23 pathways, is an alternative treatment for this group of patients.

Keywords: psoriasis, psoriatic arthritis, biologics, ustekinumab, tumor necrosis factor inhibitors

Introduction

Psoriasis is a relatively common chronic inflammatory disease that affects around 3% of the general population, and is characterized by an exaggerated proliferation of keratinocytes secondary to an activated immune system. It has a predilection for Caucasians, with an estimated prevalence of 0.2%–3.0% in the general population. The incidence is highest at the age of 20–39 years in males and 40–59 years in females, with an equal male-to-female ratio.1

Psoriasis clinically manifests as raised, well defined erythematous plaques with irregular borders and silvery scales, affecting the upper and lower extremities equally, but with a predilection for the elbows, knees, scalp, and trunk. Psoriasis vulgaris or plaque psoriasis accounts for almost 90% of the dermatological presentation of the disease, but several other forms, including guttate, inverse, erythrodermal, pustular, and palmoplantar psoriasis may occur, as well as nail involvement. Psoriasis may have significant systemic involvement, which is underscored by the coexistence of various clinical disorders, including eye, cardiovascular, and intestinal problems, metabolic syndrome, and joint inflammation. It has a very high negative impact on quality of life, requires long-term treatment which usually has a high social and economic impact, and is also associated with a decreased life span.2,3

Our understanding of the pathogenetic events leading to psoriasis has improved significantly in recent years. It is well established that an interplay of environmental,
genetic, and immunological mechanisms is associated with development of the disease, and this has also led to the development of biologics resulting in significant advances in the management of severe or refractory forms of the disease.\textsuperscript{4–6} Three classes of biologics have been introduced, including T cell inhibitors, tumor necrosis factor (TNF-\(\alpha\)) inhibitors, and most recently, ustekinumab, a biologic that targets the p40 subunit common to interleukins 12 and 23.\textsuperscript{7}

This review focuses on the effectiveness of biological therapy, particularly ustekinumab, in the treatment of psoriasis, and attempts to provide a comparative assessment of the different classes of biologics available for the treatment of psoriasis. In order to accomplish this, we have used the Psoriasis Area and Severity Index 75 (75% response) score to compare the efficacy of current biologics. A recently published systematic review that analyzed all of the different clinical severity scores used for psoriasis concluded that the Psoriasis Area and Severity Index score has been the instrument used the most extensively and is now thoroughly validated.\textsuperscript{8}

**Pathophysiology**

Genetic studies have clearly demonstrated that the incidence of psoriasis is higher among first- and second-degree relatives of patients with psoriasis than in the general population and, to date, nine chromosomal loci have been recognized as having a high predisposition for psoriasis. These are classified as susceptibility genes \textit{PSORS1} through to \textit{PSORS9}, with \textit{PSORS1} being the most prevalent and accounting for almost 50% of heritability.\textsuperscript{9,10} \textit{PSORS2}, \textit{PSORS3}, and \textit{PSORS4} are also associated with loci of susceptibility for metabolic syndrome, type 2 diabetes, familial hyperlipidemia, and cardiovascular disease. Genome-wide association studies have also identified several new genomic loci, and compelling evidence has shown an interaction between the HLA-C and ERAP 1 loci, implicating pathways that integrate epidermal barrier dysfunction with innate and adaptive immune dysregulation in psoriasis.\textsuperscript{11} CDKAL1 is also associated with type 2 diabetes genes with known function in cardiovascular risk, such as the ApoE4 isoform of apoprotein E, which is significantly more prevalent in patients with chronic plaque and guttate psoriasis than in controls.

A great body of evidence has accumulated in support of an important role for dysregulation of the immune system in the development of skin involvement in psoriasis, especially in the interplay between cells of the innate and adaptive immune systems and their inflammatory mediators in the skin epithelium and connective tissue (see Figure 1). It is still a matter of debate whether the epidermis, dermis, or a combination of both sites is primarily affected. One of the dysregulated immune mechanisms in psoriasis involves plasmacytoid dendritic cells and their high production of type I interferon (IFN-\(\alpha\)) signal, which has been shown to be present in early skin lesions of psoriatic patients.\textsuperscript{12,13} Plasmacytoid dendritic cells are activated through complexes of antimicrobial peptides LL-37 cathelicidin and DNA in a toll-like receptor-9-dependent manner, which may explain how immunological tolerance is disrupted in patients with psoriasis.\textsuperscript{14}

More recently, increasing attention has been focused on keratinocytes, and substantial evidence suggests that these cells are a direct target for a specific set of cytokines, leading to regulation of their biological properties, such as secretion of cytokines, chemokines, and antimicrobial peptides, and their differentiation and migration capacities.\textsuperscript{15}

Psoriasis is now considered the paradigm of an inflammatory disease involving the proinflammatory T helper (Th17) subset.\textsuperscript{16,17} In vitro studies have characterized certain cytokines as being able to induce specific expression patterns related to the innate immune response, such as interleukin 1a, TNF-\(\alpha\), interleukin 17a, and oncostatin M, and may be able to induce skin inflammation reminiscent of psoriasis in animal models.\textsuperscript{18}

Guilloteau et al identified an optimal and relevant cytokine combination able to synergize in vitro in order to generate an inflammatory keratinocyte model capturing some features of lesional psoriatic skin.\textsuperscript{19} In vitro and in vivo analyses were performed using normal and psoriatic skin samples, keratinocyte cell cultures, and murine models of skin inflammation. Following screening of 36 different cytokines, interleukins 1a, 1b, 6, 17a, 22, and 24, oncostatin M, and TNF-\(\alpha\) were identified as being able to modify the expression of at least five genes. Among these, interleukins 1a, 17a, and 22, as well as oncostatin M and TNF-\(\alpha\), showed the strongest synergistic activity in the production of B defensin and CXCL8. Interleukin 17a and TNF-\(\alpha\) were shown to be more crucial to the activity of this combination. It was concluded that the synergistic activity of several cytokines on keratinocytes is implicated in the pathogenesis of the disease.\textsuperscript{20}

Psoriatic skin and synovial fluid from patients with psoriatic arthritis are rich in various cytokines, including interleukins 6, 17, and 23, as well as ROR\(\gamma\) (necessary for the induction of interleukin 1R1 and 23R receptor expression), which eventually mediates the activation of nuclear factor \(\kappa\)B and Stat signaling for further Th17 differentiation and lineage commitment.\textsuperscript{21} The pathogenetic role of Th17 cells is further supported by the increased concentrations of the p40 subunit of interleukins...
12, 23, and 17 that are overexpressed in the affected skin and psoriatic joints.22,23 Many of the molecules involved in the immunological response are targeted by the newer biologics, including ustekinumab, and are the focus of this discussion.

**Treatment**

Conventional treatment includes topical agents, phototherapy, and/or systemic immunosuppressive agents. However, therapy for moderate to severe or refractory psoriasis has been revolutionized with the introduction of biologics in the past 7–10 years.24–27 The first US Food and Drug Administration (FDA) biologic approved for plaque psoriasis was alefacept in January 2003, and this was followed by six other agents, ie, efalizumab in October 2003, infliximab in September 2006, etanercept and adalimumab, and most recently, ustekinumab, approved in September 200928 (Table 1).

The overall efficacy and safety profile of biological therapy is well established. However, long-term safety data are lacking, and caution with its use should be taken into consideration due to an increase risk of opportunistic infections, worsening of heart failure, development of neurologic disease, and malignancy. Efalizumab was voluntarily withdrawn from the market in June 2009, due to a potential risk of patients developing progressive multifocal leukoencephalopathy.29

**Alefacept**

Alefacept was the first biologic introduced for the treatment of moderate to severe psoriasis. Alefacept is a human fusion protein of the CD2-binding region of leukocyte function-associated antigen-3 and the CH2 and CH3 domains of immunoglobulin G, and acts to inhibit T cell activation and induces apoptosis of memory T cells.25

The first relevant clinical trials used alefacept as monotherapy for chronic plaque psoriasis. Ellis et al conducted a multicenter, randomized, controlled Phase II trial of 229
patients who received one of three doses of intravenous alefacept (0.025 mg, 0.075 mg, or 0.150 mg/kg) or placebo for 12 weeks, with a 12-week follow-up. The PASI 75 score improved by 38% to 53% in the alefacept group compared with 21% in the placebo group. Long-term follow-up in these groups of patients showed a sustained response for up to 10 months, some even up to 18 months before retreatment.25,30

Phase III clinical trials have shown similar results regarding alefacept. Menter et al determined the efficacy of multiple courses of alefacept in patients who failed to achieve a >50% reduction in PASI after their first course of treatment. They demonstrated that multiple-course therapy in these patients had almost a double increase in achieving PASI 75 scores, from 29% to 54% in patients receiving one course compared with five courses of treatment.31

Two other randomized, double-blind, placebo-controlled Phase III studies were performed to evaluate the efficacy and tolerability of alefacept in patients with chronic plaque psoriasis. Alefacept administered intravenously or intramuscularly was shown to be effective and well tolerated for chronic plaque psoriasis.27,28 At a dosage of 5 mg/kg over 2–3 hours at baseline, and the majority continued to receive concomitant treatment at the time of study enrollment. It was concluded that alefacept was commonly added to other antipsoriatic therapies in Canada, and may allow for dosage reduction or discontinuation of concomitant systemic agents or phototherapy.24,35

Several studies have shown that alefacept is the least commonly prescribed biological therapy for psoriasis, but is a safe and well tolerated drug, with fatigue and arthralgia as the main adverse reactions, and an incidence of around 20%.36,37

However, as with most new emerging therapeutic agents, cost has become an important factor regarding treatment of patients. In a recent study, Beyer and Wolverton analyzed the total cost of systemic psoriasis therapies, concluding that the total cost of alefacept administered as two 12-week courses was around US $30,000 compared with an approximate cost of US $1000 for methotrexate.38

### TNF inhibitors

Anti-TNF-α agents were the next class of biologics to be approved by the FDA for the treatment of moderate to severe chronic plaque psoriasis, with infliximab being the first approved. Its potential beneficial use for the treatment of psoriasis was recognized following the observation of elevated levels of anti-TNF in both skin and serum, which have a positive correlation with disease activity scores and a significant reduction after successful treatment.39

#### Infliximab

Infliximab is a chimeric monoclonal antibody formed from murine and human DNA sequences by binding a mouse variable region and a human IgG1-α constant region. It has the ability to bind to both forms of TNF, and transmembrane and soluble receptors, thus achieving complete blockade of TNF-α.27,28 At a dosage of 5 mg/kg over 2–3 hours at baseline, at weeks 2 and 6, and every eight weeks thereafter, infliximab showed an average 80% response on PASI scores. In the pivotal clinical trials, 80% of patients achieved a PASI

| Biologic          | Structure                          | Dosage                       | Efficacy          | Major                  |
|-------------------|------------------------------------|------------------------------|-------------------|------------------------|
| **Alefacept**     | Human LFA-3                         | 15 mg qw for 12 weeks        | week 14%–33%      | Lymphopenia            |
| **(Amevive®)**    | Fusion protein                      | repeat qw for 12 weeks       | week 24%–60% (PASI 50) | Infusion reactions     |
| **Infliximab**    | Chimeric monoclonal                | 5 mg/kg: 0, 2, 6, qw         | week 10%–80%      | Opportunistic infections |
| **(Remicade®)**   | anti-TNF-α antibody                 |                              | week 24%–82%      |                        |
| **Etanercept**    | Human p75 TNF-receptor              | 50 mg biw for 12 weeks       | week 12%–49%      | Injection site reactions |
| **(Enbrel®)**     | Fc fusion protein                   | 50 mg qw                     | week 24%–54%      | Opportunistic Infections |
| **Adalimumab**    | Human monoclonal                   | 80 mg loading dose           | week 16%–71%      | Injection site reactions |
| **(Humira®)**     | anti-TNF-α antibody                 | 40 mg qwow                   | week 24%–70%      | Opportunistic infections |
| **Ustekinumab**   | Human monoclonal                   | 90 mg: 0, 4, q12w            | week 12%–66%      |                        |
| **(Stelara®)**    | anti-p40 antibody                   |                              | week 40%–90%      |                        |

**Table 1: Biologic agents: general characteristics**

**Abbreviations:** biw, twice weekly; LFA, lymphocyte function associated antigen; PASI, psoriasis area and severity index; TNF, tumor necrosis factor.
75 score at week 10 and 60% achieved a sustained response at week 50, with a 90% improvement in the Dermatology Life Quality Index.40,41

One of the most remarkable effects of infliximab is the rapid response seen, noted even during the first two weeks of treatment.42 Nearly half rheumatoid arthritis patients treated with infliximab develop anti-infliximab antibodies within the first year of treatment, and the concomitant use of other immunosuppressive agents, especially methotrexate, could prevent new antibody formation.43,44

**Etanercept**

Etanercept is a recombinant human TNF-α receptor (p75) protein fused to the Fc portion of IgG1, that binds not only the TNF-soluble and transmembrane portions, but also lymphotoxin-α. Similar to other TNF inhibitors, etanercept is also approved for the treatment of other autoimmune conditions, such as spondyloarthopathies and rheumatoid arthritis.28 Etanercept is administered for psoriasis at a dose of 50 mg subcutaneously twice a week for the first 12 weeks and thereafter once a week. Efficacy has been reported in many pivotal trials, with an average of 50% of patients achieving a PASI 75 score at week 12 compared with 4% in the placebo groups, and 60% of patients achieving PASI 75 at week 24 after continuous treatment.45-47 The presence of nonneutralizing anti-etanercept antibodies occurs in a small proportion of psoriasis patients and is not related to a decreased response to therapy. Neutralizing antibodies have not been described to date.48

**Adalimumab**

Adalimumab is the first fully humanized monoclonal antibody against TNF-α. Like infliximab and etanercept, adalimumab inhibits both and TNF-soluble and transmembrane particles, and also the two surface receptor ligands, p75 and p55. Adalimumab is administered as a subcutaneous injection with a usual dose for psoriasis patients of 80 mg in the first week, 40 mg in the second week, and 40 mg every two weeks thereafter in a continuous fashion. In the pivotal study of adalimumab for psoriasis, the clinical response observed was 70% in patients achieving PASI 75 scores at week 15 compared with 7% in patients on placebo.49,50 Development of antiadalimumab antibodies may occur in up to 20% of patients with rheumatoid arthritis, and may influence response to treatment.51

**Ustekinumab**

Ustekinumab is the latest biologic approved by the FDA for the treatment of moderate to severe plaque psoriasis. It is a human monoclonal antibody generated from transgenic mice by genetic engineering techniques. The main target of this biologic is the p40 subunit shared by two cytokines, interleukin 12 and 23, thereby preventing its interaction with the receptor and thus blocking subsequent signaling, differentiation, and cytokine production.52 Both cytokines are mainly produced by activated dendritic cells. Interleukin 12 mainly activates Th1 IFN-γ, TNF-α, and cells producing interleukin 2, whereas interleukin 23 has a main role in the development of Th17 and interleukin 22, and cells producing TNF-α.53

When the drug was designed, the intention was to test it in patients with ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and multiple sclerosis, because experimental mouse model analyses demonstrated blockade of interleukins 12 and 23, with subsequent prevention of arthritis and colitis.54

The most important clinical trials of ustekinumab for psoriasis are PHOENIX-1 and PHOENIX-2. Both are large-scale, placebo-controlled Phase III trials designed to evaluate the efficacy and safety of the drug in patients with moderate to severe plaque psoriasis.55,56

The primary outcome in both studies was the proportion of patients achieving ≥75% improvement in PASI 75 scores at week 12 compared with baseline. The secondary outcomes included the Physician Global Assessment score of minimal or cleared psoriasis at week 12, a change from baseline in the Dermatology Life Quality Index at week 12, and in the randomized withdrawal phase, time to loss of PASI 75 response in the group receiving maintenance ustekinumab compared with the group withdrawn from the drug at week 40. According to the inclusion criteria, patients had to be aged over 18 years, with a diagnosis of plaque psoriasis for at least six months, be candidates for phototherapy or systemic treatment, have more than 10% of body surface area involvement, and a PASI 75 score ≥12. Exclusion criteria were mostly the same for other studies of biologics, ie, no symptoms of active tuberculosis, no recent serious infections, no known malignancy, and no recent treatment with biologic or topical agents.

In PHOENIX 1 and PHOENIX 2, 766 and 1230 patients with similar baseline characteristics were randomized, respectively, with almost two-thirds having been previously treated with phototherapy and one-half having been treated previously with conventional systemic treatments and/or biologics55,56 (Table 2).

In PHOENIX 1, patients were randomized to receive ustekinumab 45 mg or 90 mg, or placebo, at weeks 0 and 4 and then every 12 weeks thereafter. At week 12, patients in the placebo group were rerandomized to receive ustekinumab
45 mg or 90 mg, with a subsequent dose at week 16 and every 12 weeks thereafter. At week 28, all partial responders (defined as PASI score 50–75) were switched to dosing every eight weeks and all nonresponders (defined as PASI score <50) had their therapy discontinued, but continued to be followed up. At week 40, all partial responders were switched to dosing every eight weeks, and responders (defined as PASI >75) were allocated to treatment continuation or treatment interruption. The PHOENIX 2 study was identical to PHOENIX 1, and all patients in both studies were to be followed up for five years.

In both trials, treatment with ustekinumab induced a rapid response rate, with a higher proportion of patients achieving PASI 50 from baseline by week 2 and PASI 75 by week 4, compared with placebo.

Approximately 70% of the patients achieved the primary endpoint of PASI 75 at week 12 compared with 3% for the placebo group in both trials at the 45 mg dose and an almost 80% response rate with the 90 mg dose at week 12. The highest response rate was achieved at week 24, with a 76% response in the 45 mg group and an 85% response in the 90 mg group. At week 28, more than 90% of patients were classified as partial responders and 50% of patients achieved a PASI 90 response rate, and efficacy was maintained until week 40 with dosing every 12 weeks.

Regarding safety and tolerability, there were no significant adverse events at both doses (45 mg versus 90 mg) compared with placebo in either trial, and no anaphylactic reactions or serum sickness was observed. Furthermore, rates of infections were similar in both groups, with upper respiratory tract infections being the most common adverse events in approximately 13% in each group.

The only head-to-head comparison of biological therapy in patients with psoriasis was the ACCEPT (Efficacy and Safety of Ustekinumab Compared to Etanercept in the Treatment of Subjects with Moderate to Severe Plaque Psoriasis) trial, which was a comparison of etanercept and ustekinumab in 900 patients. In the etanercept group, patients received etanercept 50 mg twice a week for 12 weeks, while two groups of patients received ustekinumab every 8 weeks until week 76 end of study. Phoenix I was designed in the same way as Phoenix I but the only difference is that at week 28 partial responders were assigned to receive ustekinumab every 8 weeks and the study ended at week 52, the same nonresponders were discontinued from study.

### Table 2 Ustekinumab: Phase III clinical trials

| Phoenix I | Primary endpoint |
|-----------|------------------|
| N         | Dosing          | Week      | PASI 75 response | Maximum efficacy |
| 255       | 45 mg           | 0, 4, q12w | 67%   | Week 12       | 76%   | Week 24       | 71%   |
| 256       | 90 mg           | 0, 4, q12w | 66%   | Week 12       | 85%   | Week 24       | 78%   |
| 255       | Placebo         |           | 3%    | Week 12       |       | Week 24       |       |
| Placebo randomized | n = 123 | 45 mg | Week 12       | 66%   |
|           | n = 119 | 90 mg | Week 12       | 85%   |

| Phoenix II | Primary endpoint |
|------------|------------------|
| N          | Dosing          | Week      | PASI 75 response | Maximum efficacy |
| 411        | 90 mg           | 0, 4, q12w | 76%   | Week 20       | 84%   | Week 28       | 75%   |
| 410        | Placebo         |           | 4%    | Week 20       |       | Week 28       |       |
| Placebo randomized | n = 193 | 45 mg | Week 12       | 70%   |
|           | n = 194 | 90 mg | Week 12       | 79%   |

**Notes:** Phoenix I was designed in a three-way group 1:1:1 (ustekinumab 45, 90- and placebo with treatment at week 0, 4, and every 12 weeks) with primary endpoint evaluating PASI 75 response at week 12. At that point placebo group was randomized into two groups (ustekinumab 45 and 90 mg with treatment at week 12, 16, and every 12 weeks). Therefore primary endpoint for the placebo randomized groups was at week 28. At week 28 in all three groups nonresponders (PASI <50) were discontinued from study, partial responders (PASI 50 to <75) began dosing every 8 weeks and PASI responders (>75) continued every 12 weeks. At week 40 patients from the responders groups were re-randomized to either placebo or continue every 12 weeks and patients from the placebo group who were randomized to treatment returned to placebo and at loss of therapeutic effect were started back on ustekinumab with the last dose they were receiving. At that point nonresponders or partial responders were given ustekinumab every 8 weeks until week 76 end of study. Phoenix II was designed in the same way as Phoenix I but the only difference is that at week 28 partial responders were assigned to receive ustekinumab every 8 weeks and the study ended at week 52, the same nonresponders were discontinued from study.
Institute for Health and Clinical Excellence guidance issued as a result of the single technology appraisal process states that ustekinumab is recommended as a treatment option for adults with plaque psoriasis, but a number of criteria need to be met.58

The potential for infectious, malignant, metabolic, cardiovascular, and paradoxical complications should always be considered, and further studies are needed to assess the role of ustekinumab in the treatment of other musculoskeletal and extra-articular clinical conditions and comorbidities.24 However, it should be noted that ustekinumab has been shown to improve symptoms of anxiety, depression, and health-related quality of life significantly.59,60

Briakinumab (ABT-874) is another interleukin 12 and 23 inhibitor which is currently in Phase III clinical trials. Its efficacy for moderate to severe psoriasis appears to be comparable with that of ustekinumab.61 An abstract recently presented to the American Academy of Dermatology showed that 11 major adverse cardiovascular events were observed during the open-label extension study, in addition to seven from one run-in study. Using a composite of four cardiovascular risk factors, a retrospective analysis revealed that major adverse cardiovascular events occurred at a rate of <0.3 events/100 patient-years in patients with one or fewer risk factors compared with >2.0 events/100 patient-years in those with two or more risk factors. It was concluded that this interim analysis supports the need to monitor closely for adverse events of infection, malignancies, and cardiovascular risk factors that may contribute to major adverse cardiovascular events in patients receiving briakinumab for the treatment of moderate to severe psoriasis.61

Of interest, a series of reports has shown that ustekinumab-treated patients exhibit significant improvement in histological measures of psoriasis, with minimal impact on the systemic immune response.62 No changes in serum TNF-α concentrations were seen, or any significant variation in the percentages of cells expressing CD45RA, CD45RO, CD25, HLA-DR, and CXCR3 chemokine. In addition, no apparent effect on the magnitude of Th1/Th2 responses to external stimuli in peripheral blood mononuclear cells was observed following treatment with placebo or ustekinumab.62 Furthermore, administration of ustekinumab to both Cynomolgus monkeys and humans revealed that treatment does not significantly impair recall immune system functions, or have adverse effects on prenatal or postnatal development.63,64

In conclusion, accumulating evidence supports the efficacy and safety of ustekinumab for the treatment of moderate to severe psoriasis. There is some suggestion from head-to-head comparisons that ustekinumab may offer some advantage over TNF-α inhibitors. However, there is a need for larger and longer-term studies to assess the safety profile, cost-effectiveness, and advantages of anti-interleukin 12 and 23 activity in the modern era of biological therapy.65

Disclosure
The authors report no conflicts of interest in this work.

References
1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:469–509.
2. Lebwohl M. Psoriasis. Lancet. 2003;361:1197–1204.
3. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510–518.
4. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873.
5. BraunFalco O, Burg G. Inflammatory infiltration in psoriasis vulgaris: A cytochemical study. Arch Klin Exp Dermatol. 1970;236:297–314.
6. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–1912.
7. Warren RB, Griffiths CE. The future of biological therapies. Semin Cutan Med Surg. 2010;29:63–66.
8. Puzenat E, Bransoud V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:10–16.
9. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6:813–820.
10. Bowcock AM, Barker JN. Genetics of psoriasis: The potential impacts on new therapies. J Am Acad Dermatol. 2003;49 Suppl S51–S56.
11. Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42:985–990.
12. Funk J, Langeland T, Schruppf E, Hanssen LE. Psoriasis induced by interferon-alpha. Br J Dermatol. 1991;125:463–465.
13. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid dendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202:135–143.
14. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564–569.
15. Madonna S, Scarponi C, Sestito R, et al. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Kruppel-like factor-4 and is dysregulated in psoriatic keratinocytes. J Immunol. 2010;185:2467–2481.
16. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950–957.
17. Steiman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139–145.
18. Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118:597–607.
19. Guillolette K, Paris I, Pedretti N, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J Immunol. 2010;184:5263–5270.
63. Martin PL, Sachs C, Imai N, et al. Development in the Cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. *Birth Defects Res B Dev Reprod Toxicol.* 2010;89:351–363.

64. Brodmerkel C, Zhu Y, Jiao Q, et al. Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. *J Drugs Dermatol.* 2010;9:677–683.

65. Ionescu MA, Lipozencic J. Could anti IL12/23 therapy replace anti-TNF biologics? *Acta Dermatovenerol Croat.* 2009;17:166–169.